Creative Planning Sells 9,537 Shares of Nuvation Bio Inc. (NYSE:NUVB)

Creative Planning lowered its stake in shares of Nuvation Bio Inc. (NYSE:NUVB) by 43.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 12,640 shares of the company’s stock after selling 9,537 shares during the quarter. Creative Planning’s holdings in Nuvation Bio were worth $29,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Principal Financial Group Inc. increased its position in shares of Nuvation Bio by 58.7% during the 2nd quarter. Principal Financial Group Inc. now owns 25,950 shares of the company’s stock valued at $76,000 after purchasing an additional 9,603 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Nuvation Bio by 913.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 11,095 shares of the company’s stock valued at $32,000 after acquiring an additional 10,000 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Nuvation Bio in the 2nd quarter valued at $29,000. Xponance Inc. bought a new position in Nuvation Bio in the 2nd quarter valued at $33,000. Finally, Caxton Associates LP bought a new position in Nuvation Bio in the 2nd quarter valued at $43,000. Institutional investors own 61.67% of the company’s stock.

Insider Buying and Selling at Nuvation Bio

In other Nuvation Bio news, Director Robert Mashal purchased 100,000 shares of the firm’s stock in a transaction on Tuesday, October 8th. The stock was bought at an average cost of $2.20 per share, for a total transaction of $220,000.00. Following the completion of the purchase, the director now owns 100,000 shares in the company, valued at $220,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.07% of the stock is currently owned by company insiders.

Analyst Ratings Changes

NUVB has been the topic of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Nuvation Bio in a research report on Thursday, November 7th. HC Wainwright cut their price objective on Nuvation Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Finally, Royal Bank of Canada increased their price target on Nuvation Bio from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Nuvation Bio has an average rating of “Buy” and an average target price of $6.60.

Nuvation Bio Stock Performance

Shares of NYSE NUVB opened at $2.95 on Thursday. Nuvation Bio Inc. has a 1-year low of $1.21 and a 1-year high of $4.16. The business has a fifty day moving average price of $2.55 and a 200 day moving average price of $2.91.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The business had revenue of $0.73 million during the quarter. On average, research analysts predict that Nuvation Bio Inc. will post -0.4 EPS for the current year.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.